GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Technologies Ltd (STU:DU8) » Definitions » 12-1 Month Momentum %

Genetic Technologies (STU:DU8) 12-1 Month Momentum % : -5.00% (As of May. 11, 2024)


View and export this data going back to . Start your Free Trial

What is Genetic Technologies 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-05-11), Genetic Technologies's 12-1 Month Momentum % is -5.00%.

The industry rank for Genetic Technologies's 12-1 Month Momentum % or its related term are showing as below:

STU:DU8's 12-1 Month Momentum % is ranked worse than
73.93% of 234 companies
in the Medical Diagnostics & Research industry
Industry Median: -20.39 vs STU:DU8: -5.00

Competitive Comparison of Genetic Technologies's 12-1 Month Momentum %

For the Diagnostics & Research subindustry, Genetic Technologies's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genetic Technologies's 12-1 Month Momentum % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Technologies's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Genetic Technologies's 12-1 Month Momentum % falls into.



Genetic Technologies  (STU:DU8) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genetic Technologies  (STU:DU8) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Genetic Technologies 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Genetic Technologies's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Genetic Technologies (STU:DU8) Business Description

Traded in Other Exchanges
Address
60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.

Genetic Technologies (STU:DU8) Headlines

No Headlines